This inventor holds 1 USPTO granted patent. Top assignee: Aventis Pharma Deutschland, Gmbh. Active years: 2002.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2002
Title: Heinz Hartmut Seliger: Innovator in Oligoribonucleotide Technology
Introduction
Heinz Hartmut Seliger is a notable inventor based in Elchingen, Germany. He has made significant contributions to the field of biochemistry, particularly in the development of oligoribonucleotide analogs. His work has implications for various applications, including therapeutic interventions.
Latest Patents
Heinz Hartmut Seliger holds a patent for "Oligoribonucleotide and ribozyme analogs with terminal 3′—3′ and/or 5′—5′ linkages." This invention relates to oligoribonucleotide analogs that feature terminal 3′—3′ and/or 5′—5′ internucleotide linkages. The modification introduced by Seliger stabilizes the molecules, including ribozymes, without adversely affecting their properties, including catalytic activities.
Career Highlights
Heinz Hartmut Seliger is associated with Aventis Pharma Deutschland GmbH, where he has contributed to various research initiatives. His expertise in oligoribonucleotide technology has positioned him as a key figure in the pharmaceutical industry.
Collaborations
He has collaborated with notable colleagues, including Flavio Ramalho Ortigao and Hannelore Rösch, to advance research in his field. Their combined efforts have led to innovative solutions and advancements in biochemistry.
Conclusion
Heinz Hartmut Seliger's work in oligoribonucleotide technology exemplifies the impact of innovative thinking in the pharmaceutical industry. His contributions continue to influence research and development in biochemistry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile